Activity of voriconazole (UK-109,496) against clinical isolates of Aspergillus species and its effectiveness in an experimental model of invasive pulmonary aspergillosis Journal Article


Authors: Murphy, M.; Bernard, E. M.; Ishimaru, T.; Armstrong, D.
Article Title: Activity of voriconazole (UK-109,496) against clinical isolates of Aspergillus species and its effectiveness in an experimental model of invasive pulmonary aspergillosis
Abstract: Voriconazole, a new azole antifungal agent, showed potent activity against clinical isolates of Aspergillus spp. in vitro. For A. fumigatus, the MIC range was <0.03 to 0.5 mu g/ml and the MIC at which 90% of isolates are inhibited was 0.25 mu g/ml. In an experimental model of invasive pulmonary aspergillosis which mimics infection in humans, oral voriconazole at dosages of 30 mg/kg of body weight per day significantly delayed or prevented mortality.
Keywords: bioassay; therapy; antifungal; itraconazole; fungal-infections; mycoses; aerosol; rat model
Journal Title: Antimicrobial Agents and Chemotherapy
Volume: 41
Issue: 3
ISSN: 0066-4804
Publisher: American Society for Microbiology  
Date Published: 1997-03-01
Start Page: 696
End Page: 698
Language: English
ACCESSION: WOS:A1997WL11100035
PROVIDER: wos
PMCID: PMC163774
PUBMED: 9056016
Notes: Article -- Source: Wos
Citation Impact
MSK Authors
  1. Donald Armstrong
    242 Armstrong
  2. Edward M Bernard
    58 Bernard